EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

SGLT2 Inhibitors Between Benefits and Euglycemic Ketoacidosis: A Concise Review

Luminita-Georgeta Confederat iD, Alin-Constantin Pînzariu iD, Ionela Lacramioara Serban, Mihaela-Iustina Condurache, Oana-Maria Dragostin iD

International Journal of Molecular Sciences · 09.06.2026 · 27 (12) · 5224

DOI: 10.3390/ijms27125224 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 09.06.2026. Verfasst von Luminita-Georgeta Confederat und 4 weiteren Autor:innen. Beteiligte Einrichtung: Grigore T. Popa University of Medicine and Pharmacy Iasi, 700115 Iasi, Romania. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetic Ketoacidosis, Hypoglycemic Agents, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetes mellitus is a complex metabolic disorder whose management has moved from glycemic control to the control of risk factors through the use of new antihyperglycemic drugs with pleiotropic effects. Despite the multiple cardio–renal benefits of sodium-glucose co-transporter 2 (SGLT2) inhibitors, their prescription is often avoided due to concerns regarding side effects. This review aims to discuss the multiple benefits of SGLT2 inhibitors in balance with one of the most concerning side effects, the risk of euglycemic diabetic ketoacidosis (EDKA). A literature search was performed to identify and select articles relevant to this topic. We accessed several databases, including PubMed, Web of Science and Scopus, using appropriate keywords. We selected and evaluated randomized controlled trials, retrospective studies, systematic reviews and meta-analysis published between 2014 and 2024 supporting the multifaceted benefits of SGLT2 inhibitors and the limitations of their recommendations and focusing on the risk of EDKA. Initially designed as antidiabetic agents, SGLT2 inhibitors have demonstrated important cardio–renal benefits, these drugs being the first-line medication in patients with established cardiovascular disease, heart failure and chronic kidney disease. SGLT2 inhibitors are associated with some potential side effects, but with contradictory data concerning their prevalence and clinical relevance. From the possible side effects, EDKA is a life-threatening metabolic emergency whose incidence and recognition has increased, in particular with the use of SGLT2 inhibitors. These drugs can cause this disorder through several mechanisms, including reduced insulin secretion and increased glucagon levels, leading to free fatty acid production, which generally occurs in the presence of some risk factors such as reduced dietary carbohydrates, intercurrent illnesses, surgical stress and alcohol consumption. Through awareness of these risk factors as well as of the clinical symptoms, this condition could be promptly avoided or managed and SGLT2 inhibitors could be safely used.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsDiabetic KetoacidosisHypoglycemic AgentsDiabetes Mellitus, Type 2Humans

Stichwörter der Autor:innen

SGLT2 inhibitorsbenefitseuglycemic ketoacidosismanagementrisk factors

Substanzen

Sodium-Glucose Transporter 2 InhibitorsHypoglycemic Agents

Autor:innen und Institutionen

  • Grigore T. Popa University of Medicine and Pharmacy Iasi, 700115 Iasi, Romania.
  • "Sfântul Spiridon" County Emergency Clinical Hospital, 700111 Iasi, Romania.
  • Research Centre in the Medical-Pharmaceutical Field, Faculty of Medicine and Pharmacy, "Dunarea de Jos" University of Galati, 800008 Galati, Romania.

ORCID-Profile: Luminita-Georgeta Confederat, Alin-Constantin Pînzariu, Oana-Maria Dragostin

Zitieren

APA

Confederat, L. G., Pînzariu, A. C., Serban, I. L., Condurache, M. I., & Dragostin, O. M. (2026). SGLT2 Inhibitors Between Benefits and Euglycemic Ketoacidosis: A Concise Review. International Journal of Molecular Sciences, 27(12), 5224. https://doi.org/10.3390/ijms27125224

Vancouver

Confederat LG, Pînzariu AC, Serban IL, Condurache MI, Dragostin OM. SGLT2 Inhibitors Between Benefits and Euglycemic Ketoacidosis: A Concise Review. International Journal of Molecular Sciences. 2026;27(12):5224. doi:10.3390/ijms27125224

BibTeX
@article{Confederat2026,
  author = {Confederat, Luminita-Georgeta and Pînzariu, Alin-Constantin and Serban, Ionela Lacramioara and Condurache, Mihaela-Iustina and Dragostin, Oana-Maria},
  title = {SGLT2 Inhibitors Between Benefits and Euglycemic Ketoacidosis: A Concise Review},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {12},
  pages = {5224},
  doi = {10.3390/ijms27125224}
}
Kostenlos starten →